Anti-CD45 ( DrugBank: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
60	Aplastic anemia	1
65	Primary immunodeficiency	1
285	Fanconi anemia	2

60. Aplastic anemia

Clinical trials : 245 / Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00590460 (ClinicalTrials.gov)	July 2001	26/12/2007	Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia	Cd45 (Yth-24 and Yth 54) and Cd52 (Campath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia	Fanconi Anemia;Severe Aplastic Anemia	Biological: CAMPATH-1H;Biological: Anti-CD45;Drug: Fludarabine;Procedure: Stem cell infusion	Baylor College of Medicine	The Methodist Hospital System;Center for Cell and Gene Therapy, Baylor College of Medicine	Terminated	N/A	N/A	All	5	Phase 1/Phase 2	United States

Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00579137 (ClinicalTrials.gov)	October 2007	19/12/2007	Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders	CD45 and Alemtuzumab Monoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Severe Combined Immunodeficiency Disease (SCID) And Other Primary Immunodeficiency Disorders	Severe Combined Immunodeficiency Disease;Severe Primary Immunodeficiency Disorder;Undefined T Cell Deficiency Disorder;Wiskott-Aldrick Syndrome	Biological: Campath -1H;Drug: Fludarabine;Biological: Anti-CD45;Procedure: Stem cell infusion	Baylor College of Medicine	Center for Cell and Gene Therapy, Baylor College of Medicine;Texas Children's Hospital	Terminated	N/A	N/A	All	3	Phase 1/Phase 2	United States

Clinical trials : 62 / Drugs : 93 - (DrugBank : 30) / Drug target genes : 30 - Drug target pathways : 144

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00586274 (ClinicalTrials.gov)	March 2002	21/12/2007	Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT	A Phase I Study Evaluating The Use Of Rft5-Dga To Deplete Alloreactive Cells For Patients With Fanconi Anemia After Haploidentical Stem Cell Transplantation	FANCONI ANEMIA	Procedure: CD34 selected haploidentical PBSCT;Drug: Fludarabine;Biological: T cell infusion;Biological: Campath 1h;Biological: anti-CD45	Baylor College of Medicine	UTSW-Dallas;Center for Cell and Gene Therapy, Baylor College of Medicine	Terminated	N/A	64 Years	Both	1	Phase 1	United States
2	NCT00590460 (ClinicalTrials.gov)	July 2001	26/12/2007	Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia	Cd45 (Yth-24 and Yth 54) and Cd52 (Campath-1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell Transplantation of Patients With Fanconi Anemia	Fanconi Anemia;Severe Aplastic Anemia	Biological: CAMPATH-1H;Biological: Anti-CD45;Drug: Fludarabine;Procedure: Stem cell infusion	Baylor College of Medicine	The Methodist Hospital System;Center for Cell and Gene Therapy, Baylor College of Medicine	Terminated	N/A	N/A	All	5	Phase 1/Phase 2	United States